The t(14;18) in diffuse large B-cell lymphoma: Correlation with germinal center-associated markers and clinical features

Applied Immunohistochemistry and Molecular Morphology

Volumn 13, Issue 2, 2005, Pages 116-123

  Xu, Yin ^a   McKenna, Robert W ^a   Doolittle, Jeffrey E ^a   Hladik, Christa L ^a   Kroft, Steven H ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

bcl 2; bcl 2 translocation; bcl 6; CD10; Diffuse large B cell lymphoma

Indexed keywords

BLEOMYCIN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PREDNISONE; PROTEIN BCL 2; PROTEIN BCL 6; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CELL DIFFERENTIATION; CHILD; CHROMOSOME TRANSLOCATION 14; CLINICAL ARTICLE; CLINICAL FEATURE; DIFFUSE LARGE B CELL LYMPHOMA; DISEASE MARKER; FEMALE; GERMINAL CENTER; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; B-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 18; DNA-BINDING PROTEINS; FEMALE; FLOW CYTOMETRY; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; NEPRILYSIN; TRANSLOCATION, GENETIC;

EID: 19444367343     PISSN: 15412016     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pai.0000129055.93199.2b     Document Type: Article

References (48)

1. Jaffe ES, Harris NL, Stein H, et al. Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001:171-174.
2. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403:503-511.
3. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937-1947.
4. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8:68-74.
5. Colomo L, Lopez-Guillermo A, Perales M, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood. 2003;101:78-84.
6. McClintock S, Perkins SL, Cleveland RP, et al. Immunohistochemical expression pattern of germinal center and activated B-cell markers correlates with prognosis in diffuse large B-cell lymphoma [abstract]. Mod Pathol. 2003;16:244A.
7. McClure RF, Macon WR, Remstein ED, et al. Prognostic markers in adult, de novo, diffuse large B-cell lymphomas: CD10, Bcl-6, Bcl-2 and Bcl2/IGH [abstract]. Mod Pathol. 2003;16:244A.
8. Weiss LM, Warnke RA, Sklar J, et al. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl J Med. 1987;317:1185-1189.
9. McDonnell TJ, Deane N, Platt FM, et al. Bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell. 1989;57:79-88.
10. Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood. 1996;88:386-401.
11. Aisenberg AC, Wilkes BM, Jacobson JO. The bcl-2 gene is rearranged in many diffuse B-cell lymphomas. Blood. 1988;71:969-972.
12. Offit K, Koduru PR, Hollis R, et al. 18q21 rearrangement in diffuse large cell lymphoma: incidence and clinical significance. Br J Haematol. 1989; 72:178-183.
13. Lipford E, Wright JJ, Urba W, et al. Refinement of lymphoma cytogenetics by the chromosome 18q21 major breakpoint region. Blood. 1987;70: 1816-1823.
14. Lee MS, Blick MB, Pathak S, et al. The gene located at chromosome 18 band q21 is rearranged in uncultured diffuse lymphomas as well as follicular lymphomas. Blood. 1987;70:90-95.
15. Yunis JJ, Mayer MG, Arnesen MA, et al. Bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. N Engl J Med. 1989;320: 1047-1054.
16. Huang JZ, Sanger WG, Greiner TC, et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood. 2002;99:2285-2290.
17. Gascoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood. 1997;90:244-251.
18. Hill ME, MacLennan KA, Cunningham DC, et al. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. Blood. 1996;88:1046-1051.
19. Kramer MH, Hermans J, Wijburg E, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood. 1998;92:3152-3162.
20. Xu Y, McKenna RW, Molberg KH, et al. Clinicopathologic analysis of CD10+ and CD10- diffuse large B-cell lymphoma. Identification of a high-risk subset with coexpression of CD10 and bcl-2. Am J Clin Pathol. 2001;116:183-190.
21. McCluggage WG, Alexander HD, McBride HA, et al. Immunohistochemical expression of CD10 and t(14;18) chromosomal translocation may be indicators of follicle centre cell origin in nodal diffuse large B-cell lymphoma. Histopathology. 2002;41:414-420.
22. Jenner MJ, Summers KE, Norton AJ, et al. JH probe real-time quantitative polymerase chain reaction assay for Bcl-2/IgH rearrangements. Br J Haematol. 2002;118:550-558.
23. Akasaka T, Akasaka H, Yonetani N, et al. Refinement of the BCL2/immunoglobulin heavy chain fusion gene in t(14;18)(q32;q21) by polymerase chain reaction amplification for long targets. Genes Chromosomes Cancer. 1998;21:17-29.
24. Barrans SL, Evans PA, O'Connor SJ, et al. The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome. Clin Cancer Res. 2003;9:2133-2139.
25. Fang JM, Finn WG, Hussong JW, et al. CD10 antigen expression correlates with the t(14;18)(q32;q21) major breakpoint region in diffuse large B-cell lymphoma. Mod Pathol. 1999;12:295-300.
26. Uherova PRC, Schnitzer B, Singleton TP, et al. The clinical significance of CD10 antigen expression in diffuse large B-cell lymphoma. Am J Clin Pathol. 2000;115:582-588.
27. Chang CC, Cleveland RP, Perkins SL. CD10 expression and survival. Am J Clin Pathol. 2002;117:660-661. Discussion.
28. Am J Clin Pathol. 2002; 117:661-662.
29. Harada S, Suzuki R, Uehira K, et al. Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5- with CD10+ groups may constitute clinically relevant subtypes. Leukemia. 1999;13: 1441-1447.
30. Xu Y, McKenna RW, Kroft SH. Assessment of CD10 in the diagnosis of small B-cell lymphomas: a multiparameter flow cytometric study. Am J Clin Pathol. 2002;117:291-300.
31. Arber DA, Weiss LM. CD10: a review. Appl Immunohistochem. 1997;5: 125-140.
32. Linderoth J, Jerkeman M, Cavallin-Stahl E, et al. Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study. Clin Cancer Res. 2003;9:722-728.
33. Barrans SL, Carter I, Owen RG, et al. Germinal center phenotype and bcl-2 expression combined with the international prognostic index improves patient risk stratification in diffuse large B-cell lymphoma. Blood. 2002;99:1136-1143.
34. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275-282.
35. Dalla-Favera R, Ye BH, Lo Coco F, et al. Identification of genetic lesions associated with diffuse large-cell lymphoma. Ann Oncol. 1994;5(suppl 1): 55-60.
36. Butler M, Corbally N, Dervan PA, et al. BCL-6 and other genomic alterations in non-Hodgkin's lymphoma (NHL). Br J Cancer. 1997;75:1641-1645.
37. Pescarmona E, De Sanctis V, Pistilli A, et al. Pathogenetic and clinical implications of Bcl-6 and Bcl-2 gene configuration in nodal diffuse large B-cell lymphomas. J Pathol. 1997;183:281-286.
38. Vitolo U, Gaidano G, Botto B, et al. Rearrangements of bcl-6, bcl-2, c-myc and 6q deletion in B-diffuse large-cell lymphoma: clinical relevance in 71 patients. Ann Oncol. 1998;9:55-61.
39. Barrans SL, O'Connor SJ, Evans PA, et al. Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma. Br J Haematol. 2002;117:322-332.
40. Bastard C, Deweindt C, Kerckaert JP, et al. LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients. Blood. 1994;83:2423-2427.
41. Offit K, Lo Coco F, Louie DC, et al. Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. N Engl J Med. 1994; 331:74-80.
42. Cattoretti G, Chang CC, Cechova K, et al. BCL-6 protein is expressed in germinal-center B cells. Blood. 1995;86:45-53.
43. Ye BH, Cattoretti G, Shen Q, et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat Genet. 1997; 16:161-170.
44. Dent AL, Hu-Li J, Paul WE, et al. T helper type 2 inflammatory disease in the absence of interleukin 4 and transcription factor STAT6. Proc Natl Acad Sci USA. 1998;95:13823-13828.
45. Losses IS, Jones CD, Warnke R, et al. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood. 2001;98:945-951.
46. Hermine O, Haioun C, Lepage E, et al. Prognostic significance of bcl-2 protein expression in aggressive non- Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood. 1996;87:265-272.
47. Tang SC, Visser L, Hepperle B, et al. Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma: an analysis of 83 cases. J Clin Oncol. 1994;12: 149-154.
48. Skinnider BF, Horsman DE, Dupuis B, et al. Bcl-6 and Bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma: correlation with 3q27 and 18q21 chromosomal abnormalities. Hum Pathol. 1999;30:803-808.